Sage Therapeutics Inc (FRA:SG7)
€ 5.452 0.102 (1.91%) Market Cap: 325.18 Mil Enterprise Value: -211.07 Mil PE Ratio: 0 PB Ratio: 0.61 GF Score: 49/100

SAGE Therapeutics Inc to Host Sage Science Spotlight: SAGE-718 In Depth Transcript

May 20, 2021 / 12:30PM GMT
Release Date Price: €58.6 (+0.79%)
Operator

Good morning. Welcome to Sage Therapeutics' Sage Science Spotlight Webcast and Conference Call. (Operator Instructions) This call is being webcast live on the Investors and Media section of Sage's website at sagerx.com.

This call is the property of Sage Therapeutics and recording, reproduction or transmission of this call without the express written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded. I would now like to introduce Jeff Boyle, Vice President of Investor Relations at Sage.

Jeff Boyle
Sage Therapeutics, Inc. - Investor Contact

Good morning, and thank you for joining Sage Therapeutics' first Scientific Spotlight, an in-depth review of SAGE-718. Before we begin, I encourage everyone to go to the investor and media section of our website at sagerx.com, where you can find the slides that we will discuss.

I'd like to point out that we'll be making forward-looking statements, which are based on our current expectations and beliefs.

These statements are subject to certain risks

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot